Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Biodefense Global Industry Overview 2021-2030: AI and Machine Learning to Revolutionize Early Detection and Response [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $296.00 price target on the stock.
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study [Yahoo! Finance]